[go: up one dir, main page]

WO2025207900A1 - Verrou d'enveloppe d'aiguille pour dispositifs d'injection - Google Patents

Verrou d'enveloppe d'aiguille pour dispositifs d'injection

Info

Publication number
WO2025207900A1
WO2025207900A1 PCT/US2025/021778 US2025021778W WO2025207900A1 WO 2025207900 A1 WO2025207900 A1 WO 2025207900A1 US 2025021778 W US2025021778 W US 2025021778W WO 2025207900 A1 WO2025207900 A1 WO 2025207900A1
Authority
WO
WIPO (PCT)
Prior art keywords
collar
injection device
shroud
plunger
needle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/021778
Other languages
English (en)
Inventor
Alexander Hee-Hanson
Thomas LEVER
Michael Parrott
Robert Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/619,991 external-priority patent/US12427266B1/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of WO2025207900A1 publication Critical patent/WO2025207900A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/3271—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel with guiding tracks for controlled sliding of needle protective sleeve from needle exposing to needle covering position
    • A61M5/3272—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel with guiding tracks for controlled sliding of needle protective sleeve from needle exposing to needle covering position having projections following labyrinth paths
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3143—Damping means for syringe components executing relative movements, e.g. retarders or attenuators slowing down or timing syringe mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A61M2005/31508—Means for blocking or restricting the movement of the rod or piston provided on the piston-rod
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
    • A61M2005/3247—Means to impede repositioning of protection sleeve from needle covering to needle uncovering position
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body

Definitions

  • This application relates to an injection device for delivery of a medicament, e.g., to an auto-injector device.
  • An auto-injector may be described as a device which completely or partially replaces the activities involved in drug delivery from a standard syringe. Typically, these include removal of the protective syringe cap, insertion of the needle, injection of drug and possibly removal and shielding of the used needle. Administering an injection is a process which presents several risks and challenges, both mental and physical. The use of an auto-injector can bring many benefits for the user and healthcare professional.
  • the activation or hold force is too high or has a certain profile, it can lead to use issues such as incorrectly thinking the device is not working, inadvertent early removal or a wet injection site. Some users have difficulty applying this hold force during the full drug delivery time. This results in pain, discomfort, a wet injection site, early device removal and partial drug delivery.
  • an injection device comprising: an injection device body; a needle shroud retractable into the injection device body comprising a shroud pin; and a collar rotatable with respect to the injection device body and comprising a cam track engageable with the shroud pin, wherein the cam track comprises: a first portion configured to, during retraction of the needle shroud into the injection device body, guide the shroud pin from an initial position to a hold position and cause the collar to rotate relative to the injection device body from a first position to a second position; and a second portion configured to, during extension of the needle shroud from the injection device body subsequent to the retraction, guide the shroud pin from the hold position to a final position and cause the collar to further rotate relative to the injection device body from the second position to a third position, and wherein the second portion comprises a blocking portion configured to prevent extension of the needle shroud from the injection device body when the collar is held in the second position.
  • the first portion of the cam track may comprise a first angled cam track edge arranged to convert at least a portion of proximal axial motion of the needle shroud into rotational motion of the collar.
  • the blocking portion may comprise a second angled cam track edge arranged to convert at least a portion of distal axial motion of the needle shroud into rotational motion of the collar.
  • the one or more toothed beams may be configured to be held in engagement with the one or more recesses in the internal surface of the collar by an outer surface of the plunger during distal movement of the plunger.
  • the first portion of the cam track may comprise a first angled cam track edge arranged to convert at least a portion of proximal axial motion of the needle shroud into rotational motion of the collar.
  • the blocking portion comprises a second angled cam track edge may be arranged to convert at least a portion of distal axial motion of the needle shroud into rotational motion of the collar.
  • the collar may be configured to be held in the second position temporarily by a plunger release mechanism.
  • the collar may be arranged to surround one or more toothed beams of the plunger release mechanism to prevent the toothed beams from flexing outwardly when the collar is in the first position, thereby holding the plunger.
  • An internal surface of the collar may comprise one or more recesses arranged to allow one or more toothed beams of the plunger release mechanism to flex outwardly when the collar is rotated to the second position, thereby to release the plunger.
  • the one or more recesses in the internal surface of the collar may be configured to be engaged by the one or more toothed beams when the collar is in the second position, to hold the collar in the second position and prevent rotation of the collar.
  • a method for holding a needle shroud of an injection device during medicament delivery comprising: during retraction of the needle shroud into an injection device body of the injection device, guiding a shroud pin of the needle shroud from an initial position to a hold position using a first portion of a cam track of an injection device collar, the guiding causing the injection device collar to rotate relative to the injection device body from a first position to a second position; holding the collar in the second position; and while the collar is held in the second position, preventing extension of the needle shroud from the injection device body using a blocking portion of the cam track.
  • the method may further comprise releasing the collar such that it is free to rotate from its second position, responsive to completion of a movement of a plunger of the injection device to dispense a medicament.
  • the plunger release mechanism may comprise one or more toothed beams; the injection device further may comprise a plunger comprising one or more recesses, and a biasing means for biasing the plunger in a distal direction of the injection device; the one or more toothed beams may each comprise a tooth engageable with a respective recess of the one or more recesses of the plunger; and the one or more recesses and/or the one or more teeth may be shaped to urge the one or more toothed beams out of the one or more recesses when the plunger is moved in the distal direction of the injection device.
  • the method may further comprise dispensing a medicament from a syringe of the injection device.
  • FIG. 2 shows an example of collar and needle shroud for an injection device
  • FIG. 3A shows an example of an initial configuration of the collar and needle shroud prior to retraction of the needle shroud into the injection device body
  • FIG. 3B shows an example of the needle shroud retracting into the injection device body
  • FIG. 3C shows an example of a hold configuration of the collar and needle shroud
  • FIG. 3D shows an example of the collar moving as the needle shroud extends out of the injection device body
  • FIG. 3E shows an example of a locked configuration of the collar and needle shroud
  • FIG. 4B shows an example of a cross section of an injection device in a plane through the teeth of the toothed beams prior to release of the plunger
  • FIG. 4D shows an example of a cross section of the injection device of FIG. 4B in a plane through the teeth of the toothed beams during release of the plunger;
  • FIG. 4E shows a cut-away view of an example of the plunger and rear casing after an injection is completed
  • FIG. 4F shows an example of a cross section of the injection device of FIG. 4D in a plane through the teeth of the toothed beams after an injection is completed;
  • FIG. 5 shows an example comparison of force profiles of an injection device during use
  • FIG. 6 shows a flow diagram of an example method of holding a needle shroud of an injection device during medicament delivery.
  • a drug delivery device may be configured to inject a medicament into a subject such as a human or animal.
  • delivery could be sub-cutaneous, intra-muscular, or intravenous.
  • a device could be operated by a user, who may or may not be the subject. In examples where the user is not the subject, the user may be a care-giver such as a nurse or physician.
  • the device can include various types of safety syringe, pen-injector, or auto-injector.
  • the device can include a cartridge-based system that requires piercing a sealed ampule before use. Volumes of medicament delivered with these various devices can range from about 0.5 ml to about 2 ml.
  • Yet another device can include a large volume device (“LVD”) or patch pump, configured to adhere to a subject’s skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large” volume of medicament (typically about 2 ml to about 10 ml).
  • LLD large volume device
  • patch pump configured to adhere to a subject’s skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large” volume of medicament (typically about 2 ml to about 10 ml).
  • the presently described devices may also be customized in order to operate within required specifications.
  • the device may be customized to inject a medicament within a certain time period (e.g., about 3 to about 20 seconds for auto-injectors, and about 10 minutes to about 60 minutes for an LVD).
  • Other specifications can include a low or minimal level of discomfort, or to certain conditions related to human factors, shelf-life, expiry, biocompatibility, environmental considerations, etc.
  • Such variations can arise due to various factors, such as, for example, a drug ranging in viscosity from about 3 cP to about 50 cP. Consequently, a drug delivery device will often include a hollow needle ranging from about 25 to about 31 Gauge in size. Common sizes are 27 and 29 Gauge.
  • the delivery devices described herein can also include one or more automated functions.
  • one or more of needle insertion, medicament injection, and needle retraction can be automated.
  • Energy for one or more automation steps can be provided by one or more energy sources.
  • Energy sources can include, for example, mechanical, pneumatic, chemical, or electrical energy.
  • mechanical energy sources can include springs, levers, elastomers, or other mechanical mechanisms to store or release energy.
  • One or more energy sources can be combined into a single device.
  • Devices can further include gears, valves, or other mechanisms to convert energy into movement of one or more components of a device.
  • the one or more automated functions of an auto-injector may each be activated via an activation mechanism.
  • Such an activation mechanism can include one or more of a button, a lever, a needle sleeve, or other activation component.
  • Activation of an automated function may be a one-step or multi-step process. That is, a user may need to activate one or more activation components in order to cause the automated function. For example, in a one-step process, a user may depress a needle sleeve against their body in order to cause injection of a medicament. Other devices may require a multi-step activation of an automated function. For example, a user may be required to depress a button and retract a needle shield in order to cause injection.
  • activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence.
  • activation of a first automated function may activate at least two of needle insertion, medicament injection, and needle retraction.
  • Some devices may also require a specific sequence of steps to cause the one or more automated functions to occur.
  • Other devices may operate with a sequence of independent steps.
  • Some delivery devices can include one or more functions of a safety syringe, pen-injector, or auto-injector.
  • a delivery device could include a mechanical energy source configured to automatically inject a medicament (as typically found in an autoinjector) and a dose setting mechanism (as typically found in a pen-injector).
  • Auto-injectors require user actions to commence medicament delivery.
  • One of these actions may involve a user placing a needle shroud (also referred to as a needle cover or needle sleeve) against an injection site of a subject and applying an axial force to the device to cause the needle shroud to retract into the housing of the device.
  • a needle shroud also referred to as a needle cover or needle sleeve
  • the needle of the device extends beyond the needle shroud and penetrates the injection site of the subject (e.g. the subject’s skin).
  • Medicament delivery may be automatically initiated in response to the retraction of the needle shroud or in response to some other action by the user, for example the user pressing a button on the device.
  • a medicament delivery mechanism will cause medicament contained within the device to be injected into the subject via the needle.
  • the user should hold the device steady with respect to the injection site during the course of medicament delivery to ensure the needle remains steady within the subject. This is to minimise pain and/or discomfort for the subject, and to prevent a wet injection site, early device removal and/or partial medicament delivery.
  • Injection devices described herein use a latch for holding a needle shroud in a retracted position during medicament delivery.
  • the latch comprises a collar having a cam track comprising a blocking portion, and a shroud pin of the needle shroud.
  • the cam track is configured to be engaged by the shroud pin.
  • the collar is rotatable within an injection device body of the injection device such that retraction of the needle shroud into the injection device body (e.g., as the device is pressed against an injection site) causes the collar to rotate, due to engagement between the shroud pin and the cam track. Once the collar has been rotated, engagement between the shroud pin and the blocking portion prevents extension of the needle shroud from the injection device body.
  • the collar may be temporarily held by a plunger release mechanism, which prevents rotation of the collar until medicament delivery is complete.
  • the injection device comprises a control spring for biasing the needle shroud to extend out of the injection device body
  • engagement between the shroud pin and the blocking portion prevents a biasing force provided by the control spring to the needle shroud from being transferred to the injection site of the subject.
  • the user of the device may no longer need to counteract the biasing force of the control spring to hold the device steady against the injection site.
  • the device may therefore be easier to handle during medicament delivery, for example by users with impaired dexterity.
  • FIG. 1 shows a schematic example of a cross section of an injection device 100 according to one or more aspects of the present disclosure.
  • the injection device 100 is configured to inject a medicament into a subject.
  • the injection device 100 comprises an outer casing 102 (also referred to as a housing or injection device body) that encloses a reservoir 104, a plunger 106 and a rotatable collar 108.
  • the reservoir 104 typically contains the medicament to be injected, and may, for example, be in the form of a syringe.
  • the injection device 100 can also include a cap assembly 110 that can be detachably mounted to the outer casing 102. Typically a user must remove cap 110 from the outer casing 102 before device 100 can be operated.
  • casing 102 is substantially cylindrical and has a substantially constant diameter along the longitudinal axis of the device 100.
  • the injection device 100 has a distal region 126 and a proximal region 128.
  • distal refers to a location that is relatively closer to a site of injection
  • proximal refers to a location that is relatively further away from the injection site.
  • the outer casing 102 is closed at a proximal end by a rear casing 114.
  • a needle 116 and a retractable needle shroud 118 (also referred to as a “needle sleeve” or “needle cover”) extend from a distal end of the outer casing 102.
  • the retractable needle shroud 118 is biased axially in the distal direction of the injection device 100, for example using a control spring 120.
  • the needle shroud 118 is coupled to the outer casing 102 to permit axial movement of needle shroud 118 relative to the outer casing 102.
  • the shroud 118 can move in a longitudinal direction parallel to longitudinal axis 112. Specifically, movement of shroud 118 in a proximal direction relative to the casing 102 can cause a needle 116 to extend from distal region of the casing 102, and outside a distal end of the shroud 118.
  • the plunger 106 is biased towards the distal end of the injection device 100 by a biasing means, for example comprising a drive spring 122.
  • the plunger 106 is retained in an initial position by a combination of the rear casing 114 and the collar 108, preventing the biasing means from displacing the plunger 106 in the distal direction.
  • An example of such a retention mechanism is described in relation to FIGs. 4A to 4F.
  • Activation of the injection device 100 causes the collar 108 to rotate, which releases the plunger 106. Once released, the biasing means causes the plunger 106 to move in the distal direction (i.e., towards the needle 116 end of the injection device 100).
  • the plunger 106 contacts a stopper 124 in the reservoir 104, displacing the stopper 124 in the distal direction and causing medicament stored in the reservoir 104 to be expelled from the injection device 100 via the needle 116.
  • Activation of the injection device 100 can occur via several mechanisms.
  • the needle 116 may be fixedly located relative to the casing 102 and initially be located within an extended needle shroud 118. Proximal movement of the needle shroud 118 by placing a distal end of the shroud 118 against an injection site of the subject and moving the casing 102 in a distal direction will uncover the distal end of the needle 116. Such relative movement allows the distal end of the needle 116 to extend into the injection site.
  • Such insertion is termed “manual” insertion as the needle 116 is manually inserted via the user’s manual movement of the casing 102 relative to shroud 118. Retraction of the shroud 118 into the casing 102 causes the collar 108 to rotate, releasing the plunger 106.
  • Another form of activation is “automated”, whereby the needle 116 moves relative to casing 102. Such insertion can be triggered by movement of the shroud 118 and/or by another form of activation, such as, for example, user actuation of a button (not shown) of the injection device 100.
  • the user presses the needle shroud 118 against an injection site to push the needle shroud 118 at least partially into the device casing 102.
  • the exposed needle 116 is pushed into the injection site of the subject.
  • medicament is automatically dispensed from the needle 116 via an automated mechanism.
  • a user must typically hold the needle shroud 118 in the holding position for a predetermined period of time, to ensure that the correct dose of medicament is dispensed from the device 100, before removing the device 100 from the injection site.
  • the spring biasing force from the control spring 120 against which the user must apply a force to move the needle shroud 118 is one component of an “activation force” of the device 100.
  • the activation force refers to the force or force profile that the user must exert on the device 100 to move the needle shroud 118 from the extended position shown in FIG. 1 to a retracted position within the casing 102 for medicament delivery. If this force or force profile is not well balanced, it can lead to difficulty in activating the device 100 for some users, or increase the pain or anxiety associated with using the device 100.
  • the needle 116 can be retracted within the shroud 118. Retraction can occur when the shroud 118 moves distally under the biasing of the control spring 120 as a user removes the device 100 from the injection site of the subject.
  • the shroud 118 may be locked in its extended position to prevent any (substantial) proximal movement of the shroud 118 relative to the casing 102 (i.e., preventing any movement of the shroud 118 that would uncover the needle 116).
  • the shroud 118 may be locked by a needle shroud non-return element (not shown), such as a catch.
  • FIG. 2 shows an example of collar 202 and needle shroud 204 for an injection device, e.g., the injection device 100 of FIG. 1 , wherein the collar 202 and needle shroud may correspond to the collar 108 and needle shroud 118 of FIG. 1.
  • the collar 202 may be a cylindrical collar that surrounds at least a part of the injection device, e.g., a portion of a casing (such as a portion of rear casing 114 shown in FIG. 1), of the injection device.
  • the collar 202 comprises a cam track 206 on its outer surface that engages with a shroud pin 208 of the needle shroud 204.
  • the cam track 206 is configured to cooperate with the shroud pin 208 to guide the shroud pin 208 from an initial position to a hold position during retraction of the needle shroud 204 into the injection device, i.e., when the user is pressing the device against the injection site of a subject.
  • the cam track 206 causes the collar 202 to rotate relative to the injection device body (i.e., relative to the casing 102).
  • the collar 202 is configured to rotate from left to right, e.g., anticlockwise when viewed from above.
  • the cam track 206 is further configured to cooperate with the shroud pin 208 to guide the shroud pin 208 from the hold position to a final (locked) position during extension of the needle shroud 204 out of the injection device after use, i.e., when the user is removing the device from the injection site after the completion of medicament delivery.
  • the cam track 206 may be further configured to prevent retraction of the shroud 204 after the shroud pin 208 has reached the final position, i.e., after the device is removed from the injection site, using a non-return element 216 such as a catch.
  • the cam track 206 comprises a first portion 206A that causes the collar 202 to rotate by a first angle during retraction of the needle shroud 204 into the casing, from a first (rotational) position of the collar 202 (with respect to the needle shroud 204 and injection device body) to a second (rotational) position of the collar 202 (with respect to the needle shroud 204 and injection device body).
  • the first portion 206A may comprise an initial cam track portion 218 that is aligned with the longitudinal axis of the injection device, i.e., parallel with the longitudinal axis of the injection device.
  • the first portion 206A further comprises a first angled portion 210 of the cam track 206 comprising a first angled cam track edge (also referred to herein as a “ramp”).
  • the first angled portion 210 is angled with respect to the longitudinal axis of the injection device such that the shroud pin 208 applies a force to the collar 202 during at least a portion of the retraction of the needle shroud 204 into the injection device body, causing the collar 202 to rotate from its first position to its second position.
  • the first portion 206A may further comprise a final portion 220 that is aligned with the longitudinal axis of the injection device, i.e., parallel with longitudinal axis of the injection device.
  • the plunger release mechanism may be configured to engage the collar 202 to prevent the collar 202 from rotating further.
  • the plunger release mechanism may hold the collar 202 in its second position temporarily, for example during a movement of a plunger (e.g., plunger 106) of the device during medicament delivery.
  • a plunger e.g., plunger 106
  • the plunger release mechanism may release the collar 202 so that it is no longer held in the second position and is free to rotate again.
  • the cam track 206 comprises a second portion 206B that causes the collar to rotate (when the collar 202 is not held from rotation by the plunger release mechanism) by a second angle during extension of the needle shroud 204 from the casing, from the second position shown in FIG. 2 to a third (rotational) position (with respect to the needle shroud 204 and injection device body).
  • the second portion 206B may comprise an initial portion 222 of the cam track 206 that is aligned with the longitudinal axis of the injection device, and which at least partially overlaps with the final portion 220 of the first portion 206A of the cam track 206.
  • the second portion 206B comprises a blocking portion 212 of the cam track 206.
  • the blocking portion 212 is configured to prevent extension of the needle shroud 204 from the injection device body (i.e. distal movement of the needle shroud 204 from its retracted position) when the collar 202 is held in its second position by the plunger release mechanism.
  • the blocking portion 212 is arranged to be distal to the shroud pin 208 along an axis parallel to the longitudinal axis of the injection device, when the collar 202 is in its second position and the shroud pin 208 is in its hold position.
  • the blocking portion 212 is arranged to abut the shroud pin 208 or be separated by only a small axial distance from the shroud pin 208 (for example 5mm or less, 4mm or less, 3mm or less, 2mm or less, or 1mm or less) from the shroud pin 208 along an axis parallel to the longitudinal axis of the injection device, when the collar 202 is in its second position and the shroud pin 208 is in its hold position.
  • a distal movement of the needle shroud 204 and shroud pin 208 soon brings the shroud pin 208 into abutment with the blocking portion 212 (if not already abutting), to prevent (inhibit) further distal movement of the needle shroud 204.
  • the shroud pin 208 is prevented from moving distally by engagement with the blocking portion 212 and is prevented from rotating the collar 202 to move the blocking portion 212 out of engagement with the shroud pin 208, therefore further distal movement of the needle shroud 204 is prevented.
  • the blocking portion 212 of the collar 202 and the shroud pin 208 together act as a latch for holding the needle shroud 204 in its retracted position during medicament delivery.
  • the device comprises a control spring (e g., control spring 120) that exerts a spring biasing force on the needle shroud 204 to bias the needle shroud 204 distally
  • the biasing force will now be exerted by the needle shroud 204 on the blocking portion 212 of the collar 202 (via the shroud pin 208) rather than being exerted against the injection site against which the needle shroud 204 may be held in its retracted state by a user.
  • the user may no longer need to overcome the biasing force of the control spring to hold the device in place during medicament delivery, while the shroud pin 208 remains engaged with the blocking portion 212 and the collar 202 is prevented from rotating.
  • the blocking portion 212 may comprise a proximally-facing surface, such as a second cam track edge which is proximally-facing.
  • the second cam track edge may be angled with respect to the longitudinal axis of the injection device such that the shroud pin 208 applies a force to the collar 202 during at least a portion of the extension of the needle shroud 204 out of the casing after it has been retracted, causing the collar 202 to rotate (once the collar 202 is no longer held by the plunger release mechanism) from its second position to a third (rotational) position (with respect to the needle shroud 204 and injection device body).
  • the end of the first angled cam track edge and the start of the second cam track edge may partially overlap in the azimuthal direction of the collar (i.e., in the circumferential direction). This prevents the shroud pin 208 being guided back along the first angled portion during extension of the needle shroud 204 after the injection has occurred.
  • the second portion 206B may comprise a final cam track portion 214 that is aligned with the longitudinal axis of the injection device, i.e., parallel with longitudinal axis of the injection device.
  • the final cam track portion 214 may contain a non-return element 216.
  • the non-return element 216 is configured to prevent proximal retraction of the needle shroud 204 beyond the needle after the needle shroud 204 has extended from a hold position, i.e., after an injection has occurred and the device has been removed from an injection site.
  • the non-return element 216 comprises a catch.
  • the catch comprises a resilient arm 226 extending axially (i.e., longitudinally), substantially parallel with respect to the longitudinal axis of the injection device (for example, within an aperture of the collar 202).
  • the resilient arm 226 has a protrusion 224 at a free end that extends radially outwards.
  • the protrusion 224 has a ramped surface 232 that is proximally-facing and a stopping surface 234 that is distally-facing with respect to the longitudinal axis of the injection device.
  • the ramped surface 232 and stopping surface 234 are arranged such that, as the needle shroud 204 extends from its hold position to its final position, the shroud pin 208 engages and moves across the ramped surface 232 in a distal direction.
  • a reaction force between the shroud pin 208 and the ramped surface 232 as the shroud pin 308 moves across the ramped surface 232 causes the shroud pin 208 to be deflected radially outwards and/or the non-return element 216 (e.g., the protrusion 224 and resilient arm 226) to be deflected radially inwards.
  • the shroud pin 208 After the shroud pin 208 has reached a distal edge of the ramped surface 232 and has passed the stopping surface 234, the shroud pin 208 is no longer engaged with the non-return element 216. As such, the resiliency of the needle shroud 204 and/or non-return element 216 causes the shroud pin 308 and/or nonreturn element 216 to be deflected back in the opposite radial direction to before, such that the shroud pin 208 at least partially overlaps the stopping surface 234 along a radius of the device.
  • the shroud pin 208 is brought into abutment with the stopping surface 234 due to the overlap between the shroud pin 208 and stopping surface 234, with engagement between the stopping surface 234 and the shroud pin 208 preventing further proximal movement of the needle shroud 204 into the injection device body. As such, the needle shroud 204 is locked by the non-return element 216.
  • non-return element 216 is generally described herein as comprising a catch, it should be understood that other forms of non-return element 216 may be used instead.
  • the non-return element 216 may comprise a protrusion 224 having a ramped surface 232 a stopping surface 234 similar to those described previously, however the protrusion 224 may be arranged to extend from an outer surface of the collar 202 that does not comprise a resilient arm 226.
  • a nonreturn element 216 may not be present (i.e. , the needle shroud 204 may be permitted to retract to expose the needle, after extension of the needle shroud 204).
  • FIGs. 3A-E show an example of the operation of a collar 302 and needle shroud 304 of an injection device, such as the injection device 100 of FIG. 1 .
  • the collar 302 and needle shroud 304 correspond to the collar 202 and needle shroud 204 of FIG. 2.
  • FIG. 3A shows an example of an initial configuration of the collar 302 and needle shroud 304 prior to retraction of the needle shroud 304 into the injection device body, e.g., a preuse position.
  • the needle shroud 304 is in an extended position and covers a needle (not shown) of the injection device.
  • the shroud pin 308 of the needle shroud 304 is in an initial position in the cam track 306 of the collar 302, within the initial portion 318 of the first portion 306A of the cam track 306.
  • the shroud pin 308 is held in the initial position under a retaining force from the control spring (not shown), which biases the needle shroud 304 distally from the collar 302.
  • the collar 302 is shown in its first (rotational) position with respect to the needle shroud 304 and injection device body and is free to rotate. In this configuration, the collar 302 may cause the plunger of the device (not shown) to be retained in an initial position, as described later in relation to FIGs. 4A and 4B.
  • the shroud pin 308, first portion 306A and cam track 306 correspond to the shroud pin 208, first portion 206A and cam track 206 of FIG. 2.
  • FIG. 3B shows an example of the needle shroud 304 retracting into the injection device body, e.g., during activation of the injection device when a user is pressing the needle shroud 304 against an injection site of a subject (which may or may not be the user).
  • the shroud pin 308 moves along the initial part 318 (corresponding to the initial portion 218) of the first portion 306A of the cam track 306 in a proximal axial direction until it reaches the first angled portion 310 (corresponding to the first angled portion 210) of the cam track 306. Further retraction of the needle shroud 304 causes the shroud pin 308 to apply a force to the first angled portion 310 of the cam track 306, which in turn causes the collar 302 to rotate from its first position to its second position.
  • the shroud pin 308 causes the collar 302 to rotate until the shroud pin reaches an upper end of the angled portion 310, after which further retraction of the shroud 304 causes the shroud pin 308 to move into the final portion 320 of the first portion 306A of the cam track 306 and reach a hold position.
  • FIG. 3C shows an example of a hold configuration of the collar 302 and needle shroud 304, e.g., the configuration where medicament is being expelled from the injection device via a needle.
  • the collar 302 is in its second position.
  • the plunger release mechanism releases the plunger to initiate medicament delivery, as described later in relation to FIGs. 4C and 4D.
  • the plunger release mechanism also engages with the collar 302 to hold the collar 302 in its second position and prevent rotation of the collar 302, again as described later in relation to FIGs. 4C and 4D.
  • the device comprises a control spring (e.g., control spring 120) that exerts a spring biasing force on the needle shroud 304 to bias the needle shroud 304 distally
  • the biasing force will now be exerted by the needle shroud 304 on the blocking portion 312 of the collar 302 (via the shroud pin 308) rather than being exerted against the injection site against which the needle shroud 304 may be held in its retracted state.
  • a user may no longer need to counteract the biasing force of the control spring to hold the device in place during medicament delivery, while the shroud pin 308 remains engaged with the blocking portion 312 and the collar 302 is prevented from rotating from its second position.
  • FIG. 3D shows an example of the collar 302 moving as the needle shroud 304 extends out of the injection device body, e.g., during removal of the needle from the injection site after an injection has occurred.
  • the plunger release mechanism has released the collar 302 (e.g., in response to the completion of medicament delivery) such that it is once again free to rotate from its second position, for example as described later in relation to FIGs. 4E and 4F.
  • the shroud pin 308 comes into contact with the angled edge of the blocking portion 312 (if they are not already abutting).
  • the overlap of the top of the blocking portion 312 and the top of the first angled portion 310 in the azimuthal direction prevents the shroud pin 308 from returning along the first portion 306A of the cam track 306 after the needle shroud 304 has been fully retracted. Further extension of the needle shroud 304 as it moves distally causes the shroud pin 308 to apply a force to the angled edge of the blocking portion 312, causing the collar 302 to rotate from its second position (shown in FIG. 3C) to its third position (shown in FIG. 3D), with the shroud pin 308 moving across the angled edge of the blocking portion 312 in the process.
  • the shroud pin 308 moves along the angled edge of the blocking portion 312 until it reaches an edge of the blocking portion 312, after which it enters a final cam track portion 314 of a second portion 306B of the cam track 306 (corresponding to the final cam track portion 214 of the second portion 206B of the cam track 206).
  • the needle shroud 304 continues to move distally out of the injection device body, with the shroud pin 308 also moving distally through the final cam track portion 314.
  • the shroud pin 308 engages and passes over a non-return element 316 as the needle shroud 304 continues to extend out of injection device body and the shroud pin 308 moves axially, guided by the final cam track portion 314.
  • the non-return element 316 may be any non-return element 316 suitable for preventing distal retraction of the needle shroud 304, for example the nonreturn element 316 may correspond to any non-return element 216 described in relation to FIG. 2, for example having a ramped surface 232 and a stopping surface 234.
  • the injection device may comprise a damper (not shown) arranged to dampen (e.g., slow) the rotation of the collar 302 from its second position (shown in FIG. 3C) to its third position (shown in FIG. 3D).
  • the damper may be coupled to, or otherwise arranged between, the collar 302 and another portion of the device such as a rear casing (e.g., rear casing 114) or housing (e.g., outer casing 102).
  • the damper may be a viscous damper, for example comprising a viscous fluid between the collar 302 and a rotationally fixed part of the injection device.
  • the damper may provide a speed dependent torque that partially counteracts rotation of the collar 302 from its second position to its third position.
  • the time it takes for the shroud pin 308 to move along the angled edge of the blocking portion 312 until it enters the final cam track portion 314 can be increased, which may delay the sudden increase in biasing force transferred to the injection site by the control spring (via the needle shroud 304) once the collar 302 has been released for rotation by the plunger release mechanism. It may be desirable that the damper does not dampen rotation of the collar 302 from its first position to its second position, so that it does not add to the activation force required to initiate medicament delivery.
  • FIG. 3E shows an example of a locked configuration of the collar 302 and needle shroud 304, e.g., the configuration after the needle shroud 304 has extended from the device body after retraction.
  • the shroud pin 308 is locked in a final portion of the cam tack 306 by the non-return element 316, which in this example comprises a catch (e.g., as described in relation to FIG. 2).
  • the non-return element 316 prevents further retraction of the needle shroud 304 into the injection device body (and thus exposure of the needle) by engaging with the shroud pin 308 when the needle shroud 304 is moved in the proximal axial direction.
  • FIGs. 4A-F show examples of a plunger release mechanism cooperating with a collar of an injection device, such as the collar 302.
  • FIG. 4A shows a cut-away view of an example of a plunger 406 and a rear casing 414, which may correspond to the plunger 106 and rear casing 114 of FIG. 1 , prior to release of the plunger 406.
  • the rear casing 414 comprises one or more (e.g., two or three) toothed beams 424, which may form part of the plunger release mechanism.
  • Each toothed beam 424 comprises a flexible arm 426 and a tooth 428, wherein the flexible arm(s) 426 may extend substantially parallel to the longitudinal axis of the injection device.
  • the plunger 406 comprises one or more recesses 430 corresponding to the one or more toothed beams 424, which can each engage with a tooth 428 of a respective toothed beam 424.
  • the recesses 430 and toothed beams 424 are evenly spaced around the plunger 406 and rear casing 414 respectively, e.g., spaced at 180 degrees around the plunger 406 and rear casing 414 for two recesses 430 and teeth 428, spaced at 120 degrees around the plunger 406 and rear casing 414 for three recesses 430 and teeth 428, etc. While held in the recesses 430 (e.g., by the collar 402, as described in relation to FIG. 4B), the teeth 428 of the toothed beams 424 hold the plunger 406 to prevent the plunger 406 from moving in the distal direction 432 to dispense medicament.
  • each tooth 428 may comprise a bevel (e.g., be chamfered) at its proximal end (and may, in some examples also be bevelled at its distal end).
  • a bevel e.g., be chamfered
  • an upper i.e.
  • each recess 430 contacts the bevel of its respective tooth 428 and applies an outward force to the respective toothed beam 424.
  • this causes the toothed beams 424 to flex outwards, releasing the plunger 406 and allowing an injection to proceed.
  • FIG. 4B shows an example of a cross section of an injection device in a plane through the teeth 428 of the toothed beams prior to release of the plunger 406.
  • the portion of the rear casing 414 comprising the toothed beams is surrounded by the collar 402 of the injection device, which prevents the teeth 428 of the toothed beams from flexing outwards due to the force applied on them by the recess 430 of the plunger 406. Since the toothed beams are prevented from flexing outwards, they do not prevent the collar 302 from being rotated.
  • the collar 402 is free to rotate from its first (rotational) position shown in FIG. 4B to its second (rotational) position shown in FIG. 4D in response to retraction of a needle shroud into the injection device body (e.g., as described in relation to FIGs. 2 and 3B).
  • FIG. 4C shows a cut-away view of the plunger 406 and rear casing 414 of FIG 4A during medicament delivery.
  • one or more recesses 434 (as shown in FIG. 4D) in the inner surface of the collar 402 rotate over the teeth 428 of the toothed beams 424 until they are each in radial alignment with a respective tooth 428. This provides space for the toothed beams 424 to be forced outwards in a radial direction by their respective plunger recesses 430, thereby releasing the plunger 406.
  • the one or more recesses 434 may be arranged to allow release of the plunger 406 when the collar 402 is in its second position and the shroud pin (e.g., shroud pin 308) of the needle shroud enters the final part of the first portion of the cam track (e.g. cam track 306).
  • FIG. 4C shows the plunger 406 having moved in the distal direction 432 with respect to the rear casing 414 under the force of a drive spring, with the toothed beams 424 held in their radially deflected positions by contact between the teeth 428 and the outer surface of the plunger 406.
  • FIG. 4E shows a cut-away view of the plunger 406 and rear casing 414 of FIGs. 4A and 4C after medicament delivery is complete.
  • the plunger 406 has continued moving in the distal direction 432 until the toothed beams 424 are no longer held in their deflected state by the plunger 406.
  • FIG. 4E shows a proximal end of the plunger 406 having moved distally past the toothed beams 424 such that the toothed beams 424 are no longer in contact with (and deflected by) the outside surface of the plunger 406, and therefore the toothed beams 424 move inwards in a radial direction (e.g. due to resiliency of the toothed beams 424).
  • the toothed beams 424 and the plunger 406 may be configured such that the toothed beams 424 are allowed to move radially inwards and therefore disengage their respective recesses 434 in response to medicament delivery being completed (i.e., when the plunger 406 has distally moved a predetermined distance to dispense a predetermined volume of medicament).
  • FIG. 4F shows an example of a cross section of an injection device in a plane through the teeth 428 of the toothed beams after medicament delivery is complete, as previously described in relation to FIG. 4E.
  • the one or more toothed beams 424 have moved radially inwards, disengaging from their respective one or more recesses 434 and thereby once again allowing rotation of the collar 402 with respect to the plunger 406 and rear casing 414.
  • the collar 402 is now free to rotate from its second position to its third position, allowing the needle shroud to extend from the injection device body, for example as previously described with respect to FIGs 2 and 3D.
  • FIG. 5 shows an example comparison of force profiles of a prior art injection device and an injection device according to one or more embodiments of the present disclosure (e.g. as described in relation to FIGs. 1 , 2, 3A-E, 4A-F and/or 6) during use.
  • the graph shows a magnitude of a vertical force applied (in Newtons, N) by a user as a function of needle shroud displacement (in mm) during insertion and removal of a device from a subject’s body for both a prior art injection device (e.g., without having a blocking element) and a device using a collar having a blocking element as described herein.
  • the collar is held in the second position.
  • the collar may be held in the second position by a plunger release mechanism of the injection device.
  • the method comprises causing release of a plunger of the injection device when the shroud pin reaches the final part of the first portion of the cam track and the collar is in the second position.
  • one or more recesses in an inner surface of the collar may align with respective teeth on one or more toothed beams of a rear casing of the injection device, allowing toothed beams and respective teeth to be urged radially outwards by respective recesses on the plunger such that the teeth engage corresponding recesses in an inner surface of the collar.
  • the engagement between the one or more teeth and the collar prevents rotation of the collar, thereby holding the collar in its second position.
  • the holding of the collar may be only temporary, for example during a movement of the plunger to dispense the medicament.
  • the collar is released such that it is free to rotate from its second position.
  • the collar may be released to rotate by the plunger release mechanism, for example as previously described in relation to FIGS. 2, 3D, 4E and 4F.
  • the collar may be released to rotate by the plunger release mechanism responsive to completion of a movement of the plunger to dispense the medicament.
  • the shroud pin is guided from the hold position to a final position using a second portion of the cam track of the injection device collar, the guiding causing the injection device collar to rotate relative to the injection device body from its second position to a third position.
  • the rotation is in the same direction (e.g., clockwise or anticlockwise) as the rotation caused by the first portion of a cam track during retraction of the needle shroud.
  • the second portion of the cam track comprises the blocking portion, which may be angled to cause rotation of the collar from the second position to the third position when the shroud pin is urged against it.
  • the second portion of the cam track may further comprise an initial portion that is parallel to a longitudinal axis of the injection device, and that includes the hold position and extends to a start of the second angled portion.
  • the initial portion of the second portion of the cam track at least partially overlaps with the final part of the first portion of the cam track.
  • a non-return element for example any non-return element 216 or 316 as described herein.
  • drug or “medicament” are used synonymously herein and describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharmaceutically acceptable salts or solvates thereof, and optionally a pharmaceutically acceptable carrier.
  • An active pharmaceutical ingredient (“API”) in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.
  • a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more diseases.
  • API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
  • the drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device.
  • the drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs.
  • the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days).
  • the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20°C), or refrigerated temperatures (e.g., from about - 4°C to about 4°C).
  • the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be-administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber.
  • the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and/or during dispensing into the human or animal body.
  • the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing.
  • the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
  • the drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and/or prophylaxis of many different types of medical disorders.
  • disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism.
  • Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.
  • APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15th edition.
  • APIs for the treatment and/or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof.
  • an insulin e.g., human insulin, or a human insulin analogue or derivative
  • GLP-1 glucagon-like peptide
  • DPP4 dipeptidyl peptidase-4
  • analogue and “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring peptide and/or by adding at least one amino acid residue.
  • the added and/or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues.
  • Insulin analogues are also referred to as "insulin receptor ligands".
  • the term ..derivative refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g., a fatty acid) is bound to one or more of the amino acids.
  • one or more amino acids occurring in the naturally occurring peptide may have been deleted and/or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable, have been added to the naturally occurring peptide.
  • insulin analogues examples include Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Vai or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N- tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-g
  • GLP-1 , GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide (Lyxumia®), Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Victoza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C (Efpeglenatide), HM-15211 , CM-3, GLP-1 Eligen, GRMD-0901 , NN-9423, NN-9709, NN- 9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1 , CVX-096, ZYOG-1 , ZYD-1 ,
  • oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia or RG012 for the treatment of Alport syndrom.
  • DPP4 inhibitors are Linagliptin, Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
  • hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
  • Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Nafarelin
  • Goserelin Goserelin.
  • polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.
  • antibody refers to an immunoglobulin molecule or an antigenbinding portion thereof.
  • antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments, which retain the ability to bind antigen.
  • the antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody.
  • the antibody has effector function and can fix complement.
  • the antibody has reduced or no ability to bind an Fc receptor.
  • the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
  • the term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and/or a dual variable region antibody-like binding protein having cross-over binding region orientation (CODV).
  • TBTI tetravalent bispecific tandem immunoglobulins
  • CODV cross-over binding region orientation
  • fragment refers to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen.
  • Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments.
  • Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigenbinding antibody fragments are known in the art.
  • SMIP small modular immunopharmaceuticals
  • CDR complementarity-determining region
  • framework region refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding.
  • framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
  • An example drug delivery device may involve a needle-based injection system as described in Table 1 of section 5.2 of ISO 11608-1 :2014(E). As described in ISO 11608- 1 :2014(E), needle-based injection systems may be broadly distinguished into multi-dose container systems and single-dose (with partial or full evacuation) container systems.
  • the container may be a replaceable container or an integrated non-replaceable container.
  • a multi-dose container system may involve a needle-based injection device with a replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user).
  • Another multi-dose container system may involve a needle-based injection device with an integrated non-replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user).
  • a single-dose container system may involve a needle-based injection device with a replaceable container.
  • each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation).
  • each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation).
  • a single-dose container system may involve a needlebased injection device with an integrated non-replaceable container.
  • each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation).
  • each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental & Geological Engineering (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un dispositif d'injection comprend : un corps de dispositif d'injection ; une enveloppe d'aiguille comprenant une broche d'enveloppe ; et un collier pouvant tourner par rapport au corps de dispositif d'injection et comprenant une piste de came. Pendant la rétraction de l'enveloppe d'aiguille, une première partie de la piste de came guide la broche d'enveloppe vers une position de maintien et amène le collier à tourner par rapport au corps de dispositif d'injection d'une première position à une deuxième position. Pendant une extension ultérieure de l'enveloppe d'aiguille, une seconde partie de la piste de came guide la broche d'enveloppe de la position de maintien à une position finale et amène le collier à tourner davantage par rapport au corps de dispositif d'injection de la deuxième position à une troisième position, la seconde partie comprenant une partie de blocage configurée pour empêcher l'extension de l'enveloppe d'aiguille à partir du corps de dispositif d'injection lorsque le collier est maintenu dans la deuxième position.
PCT/US2025/021778 2024-03-28 2025-03-27 Verrou d'enveloppe d'aiguille pour dispositifs d'injection Pending WO2025207900A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP24167306.0 2024-03-28
US18/619,991 US12427266B1 (en) 2024-03-28 2024-03-28 Needle shroud latch for injection devices
EP24167306 2024-03-28
US18/619,991 2024-03-28

Publications (1)

Publication Number Publication Date
WO2025207900A1 true WO2025207900A1 (fr) 2025-10-02

Family

ID=95395072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/021778 Pending WO2025207900A1 (fr) 2024-03-28 2025-03-27 Verrou d'enveloppe d'aiguille pour dispositifs d'injection

Country Status (1)

Country Link
WO (1) WO2025207900A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100268170A1 (en) * 2007-09-25 2010-10-21 Becton Dickinson France S.A.S. Autoinjector
US20150258283A1 (en) * 2014-03-11 2015-09-17 Terumo Kabushiki Kaisha Liquid administration device
US20180361082A1 (en) * 2015-12-21 2018-12-20 Carebay Europe Ltd Tubular rotator for a medicament delivery device and a medicament delivery device containing the same
WO2023104512A1 (fr) * 2021-12-07 2023-06-15 Shl Medical Ag Sous-ensemble d'un dispositif d'administration de médicament

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100268170A1 (en) * 2007-09-25 2010-10-21 Becton Dickinson France S.A.S. Autoinjector
US20150258283A1 (en) * 2014-03-11 2015-09-17 Terumo Kabushiki Kaisha Liquid administration device
US20180361082A1 (en) * 2015-12-21 2018-12-20 Carebay Europe Ltd Tubular rotator for a medicament delivery device and a medicament delivery device containing the same
WO2023104512A1 (fr) * 2021-12-07 2023-06-15 Shl Medical Ag Sous-ensemble d'un dispositif d'administration de médicament

Similar Documents

Publication Publication Date Title
US12390603B2 (en) Injection device
US20240245869A1 (en) Injector Device
US20230158254A1 (en) Injector Device
US11801345B2 (en) Injector device
WO2017089290A1 (fr) Dispositif d'injection de médicament avec support d'aiguille pivotant
WO2017089287A1 (fr) Dispositif d'injection avec support d'aiguille mobile axialement
US12329952B1 (en) Medicament delivery device
US12274866B1 (en) Rotatable collar for injection devices
US12274875B1 (en) Needle shroud latch for injection devices
US12274871B1 (en) Hold detent mechanism for injection devices
US12427266B1 (en) Needle shroud latch for injection devices
US12502482B2 (en) Collar cam lock for injection devices
US20250303067A1 (en) Collar cam lock for injection devices
US12397122B1 (en) Medicament delivery device
US12337159B1 (en) Medicament delivery device
US12403266B1 (en) Medicament delivery device
US12274873B1 (en) Medicament delivery device
US12377226B1 (en) Medicament delivery device
WO2025207900A1 (fr) Verrou d'enveloppe d'aiguille pour dispositifs d'injection
US12329954B1 (en) Medicament delivery device
US12343505B1 (en) Medicament delivery device
US12434004B1 (en) Medicament delivery device
WO2025207867A1 (fr) Verrou à came à collier pour dispositifs d'injection
WO2025207902A1 (fr) Collier rotatif pour dispositifs d'injection
WO2025188599A1 (fr) Dispositif d'administration de médicament